: A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with Nec-1s solubility dmso metastatic colorectal cancer. Clin Cancer Res 2005, 11:5526–5533.PubMedCrossRef MGCD0103 in vitro 3. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O’Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz HJ: Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. J Clin Oncol 2008, 26:2320–2326.PubMedCrossRef 4. Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A, et al.: Bortezomib (PS-341,
Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006, 5:3042–3051.PubMedCrossRef 5. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J: Differential cellular and molecular effects of bortezomib, a proteasome P005091 mouse inhibitor, in human breast cancer cells. Mol Cancer Ther 2006, 5:665–675.PubMedCrossRef 6. Yang CH, Gonzalez-Angulo AM, Reuben
JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, et al.: Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006, 17:813–817.PubMedCrossRef 7. Engel RH, Brown JA, Von Roenn JH, O’Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ: A phase
II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 2007, 25:733–737.PubMedCrossRef 8. Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J: Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer 2008, 98:1500–1507.PubMedCrossRef 9. Schmid P, Kuhnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, et al.: A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 2008, 19:871–876.PubMedCrossRef 10. Papandreou CN, Logothetis CJ: Bortezomib as a potential Amylase treatment for prostate cancer. Cancer Res 2004, 64:5036–5043.PubMedCrossRef 11. Price N, Dreicer R: Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Prostate Cancer 2004, 3:141–143.PubMed 12. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al.: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108–2121.PubMedCrossRef 13.